N/A N=99 Loading Vancomycin Doses in the Emergency Department
Infectious Disease
Primary: Percentage of Participants First Achieving Therapeutic Levels at 36 Hours — 20; 18 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=139 Use of Electrical Impedence to Measure Lean Body Weight as a Determinant of the Dose of Contrast Media for Abdominal CT
IV Contrast Dosing
Primary: Difference in Enhancement of the Liver and Blood Vessels Over Time, Measured in Hounsfield Units (HU) — 116; 124; 121; 120 Hounsfield units (HU)
Phase 2 N=191 Coronary MDCTA With Iopamidol Injection 370
Coronary Artery Disease
Primary: Diagnostic Quality of Visualization of Coronary Arteries, Off-Site Reader 1 — 949; 842; 841 Segments Visualized Accurately — p=0.0099
Phase 4 N=114 Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Type 2 Diabetes · Renal Insufficiency
Primary: Average Blood Glucose Over 6 Days — 174; 174.5 milligrams per deciliter — p=.958
N/A N=48 Ketamine: Comparison of IV Push vs. IV Drip
Pain
Primary: Overall Rate of Feeling Unreality — 22; 13 Participants
Phase 4 N=13 Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients
Infection in Solid Organ Transplant Recipients
Primary: Area Under the Curve (AUC) — 21.0 mcg∙h/mL
Phase 4 N=57 Loop Diuretics Administration and Acute Heart Failure
Acute Heart Failure
Primary: Evaluation of Mean Urine Output Volume During the Infusion Period — 2505; 2140 mL — p=0.04
N/A N=78 Continuous Infusion Versus Bolus Dosing for Pain Control After Pediatric Cardiothoracic Surgery
Congenital Heart Disease
Primary: Total Morphine Dosage — 0.9; 0.23 mg/kg
N/A N=66 0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Critically Ill Children
Hyponatremia
Primary: Serum Sodium Levels in Both Groups — 137.8; 140.0 mEq/L — p=0.04
Phase 2 N=271 Sodium Chloride and Contrast Nephropathy
Kidney Failure, Chronic · Kidney Failure, Acute · Heart Failure
Primary: Number of Participants With Acute Kidney Injury During the First 48 Hours After Contrast Administration — 5; 4 Participants
Phase 3 N=33 Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)
Coronary Computed Tomographic Angiography
Primary: Contrast to Noise Ratio — 18.6; 20.5 CNR
Phase 4 N=171 Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children
Moderate, Deep Sedation
Primary: Sedation Efficacy — 5.5; 6; 6 units on a scale — p=0.2
N/A N=96 DyeVert System RCT
Coronary Angiography
Primary: Evaluate the Total Volume of CM Used Comparing the DyeVert Group to the Control Group. — 38.0; 62.5 ml
Phase 4 N=140 Intravenous Dexamethasone on Supraclavicular Brachial Plexus Block for Shoulder Arthroscopy
Shoulder Arthroscopy · Pain
Primary: Duration of Analgesia From a Supraclavicular Block Performed for Shoulder Arthroscopy — 17.4; 22.7; 20.2; 19.8 Hours
Phase 4 N=98 Sub-dissociative Dose Ketamine Dosing Study
Acute Pain
Primary: Change in Pain Score From Baseline to 30 Minutes Post Initiation of Drug Administration — 3.8; 3.5 score on a scale
Phase 4 N=122 Contrast Nephropathy and Nitrates
Contrast Induced Nephropathy
Primary: Change in GFR — 1.8; -4.1 mL/min
Phase 2 N=7 Dosing of Levetiracetam (Keppra) in Neonates
Seizures
Primary: Pharmacokinetic Profile — 0.51 ml/min/kg
Phase 4 N=299 Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis
Patient Comfort and Safety
Primary: Frequency of Subjects With Moderate/Severe Discomfort When Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis. — 53; 99 Number of…
N/A N=513 Comparison of Contrast Agents During CT Angiography
Contrast Enhancement on Cardiac CT
Primary: Image Quality of the CT Scans Using Different Contrast Agents — 333; 357; 362; 288 hounsfield units
N/A N=4 Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections
Skin and Soft Tissue Infections
Primary: Clinical Efficacy — 2; 0 participants
N/A N=190 Programmed Intermittent Epidural Bolus Time Interval and Injection Volume
Labor Pain
Primary: Total Bupivicaine in Milligrams Administered Per Hour of Labor for Analgesia. — 11.3; 11.1; 10.3 mg bupivacaine per hour — p=>0.05
N/A N=864,080 CT DOSE Collaboratory
Ionizing Radiation Exposure · Quality Improvement
Primary: Change in Mean Effective Dose (ED) — -0.13; -0.81; -0.14; -0.26 Millisieverts (mSv)
N/A N=114 DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
Chronic Kidney Disease
Primary: Percentage of Contrast Media Volume Saved — 40.1 % CMV savings per procedure
Phase 4 N=8 Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)
Critically Ill · Hemodialysis
Primary: Daptomycin Transmembrane Clearance by Continuous Venovenous Hemodialysis — 6.3 mL/min
Phase 1 N=24 Ascending Doses of Autologous FDP vs FFP
Freeze Dried Plasma in Healthy Volunteers
Primary: Safety of Single Infusions of FDP at Increasing Fixed Doses in Normal Healthy Subjects by Evaluating Vital Signs and Laboratory Tests — 4; 4; 4; 4 Participants
Phase 4 N=215 Titration of Intravenous Hydromorphone
Acute Severe Pain
Primary: Number of Participants Requesting Pain Medication in Different Patterns Over Time — 94; 20; 22; 19 Participants
Phase 4 N=157 Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose
Magnetic Resonance Imaging
Primary: Degree of Lesion Contrast Enhancement — 0.884; 0.863; 3.007; 2.979 Scores on a scale — p=< 0.0001
Phase 2 N=60 Low Dose ICG for Biliary Tract and Tumor Imaging
Cholecystitis · Hepatocellular Carcinoma · Liver Metastases
Primary: Quantitative Assessment - Bile Duct-to-liver Fluorescence Intensity Ratio — 2.7; 0.7 ratio
Phase 4 N=240 A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management
Pain
Primary: Pain Score at 30 Minutes — 5.14; 5.05; 4.81 pain score
Phase 4 N=177 Crossover Comparison of MultiHance and Dotarem
Brain Disease
Primary: Global Diagnostic Preference Between the Two Exams — 31; 51; 43; 14 participant exams — p=<0.0001